Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986;21(Suppl 1):69S–75S. doi: 10.1111/j.1365-2125.1986.tb02856.x

Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension

D Torvik, H-P Madsbu
PMCID: PMC1400760  PMID: 2939870

Abstract

1 A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension.

2 According to response, patients received doxazosin 1-16 mg once daily, prazosin 0.5-10 mg twice daily, or placebo. Mean final daily doses were doxazosin 11.3 mg and prazosin 13.8 mg.

3 Doxazosin once daily and prazosin twice daily both produced statistically significant reductions in both standing and supine blood pressures when compared with placebo. No significant differences between treatments were recorded for standing and supine heart rates.

4 Doxazosin, prazosin and placebo all had a similar effect on plasma lipid profiles, i.e. an increase in HDL/total cholesterol of approximately 10%. The differences between treatments were not statistically significant. The HDL/total cholesterol ratio significantly increased from baseline to the end of treatment for all three groups, the decrease in triglycerides being statistically significant only in the doxazosin-treated group.

Keywords: doxazosin, hypertension, lipids, prazosin

Full text

PDF
69S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayd F. J., Jr Editorial: Single daily dose of antidepressants. JAMA. 1974 Oct 14;230(2):263–264. [PubMed] [Google Scholar]
  2. Castelli W. P. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984 Feb 27;76(2A):4–12. doi: 10.1016/0002-9343(84)90952-5. [DOI] [PubMed] [Google Scholar]
  3. Elliott H. L., Meredith P. A., Sumner D. J., McLean K., Reid J. L. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. Br J Clin Pharmacol. 1982 May;13(5):699–703. doi: 10.1111/j.1365-2125.1982.tb01439.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gatley M. S. To be taken as directed. J R Coll Gen Pract. 1968 Jul;16(1):39–44. [PMC free article] [PubMed] [Google Scholar]
  5. Goto Y. Effects of alpha- and beta-blocker antihypertensive therapy on blood lipids: a multicenter trial. Am J Med. 1984 Feb 27;76(2A):72–78. doi: 10.1016/0002-9343(84)90959-8. [DOI] [PubMed] [Google Scholar]
  6. Helgeland A., Hjermann I., Leren P., Enger S., Holme I. High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study. Br Med J. 1978 Aug 5;2(6134):403–403. doi: 10.1136/bmj.2.6134.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med. 1980 Nov;69(5):725–732. doi: 10.1016/0002-9343(80)90438-6. [DOI] [PubMed] [Google Scholar]
  8. Lees R. S., Lees A. M. High-density lipoproteins and the risk of atherosclerosis. N Engl J Med. 1982 Jun 24;306(25):1546–1548. doi: 10.1056/NEJM198206243062509. [DOI] [PubMed] [Google Scholar]
  9. Leren P. Effect of alpha- and beta-blocker therapy on blood lipids: European experience. Am J Med. 1984 Feb 27;76(2A):67–71. doi: 10.1016/0002-9343(84)90958-6. [DOI] [PubMed] [Google Scholar]
  10. Leren P., Foss P. O., Helgeland A., Hjermann I., Holme I., Lund-Larsen P. G. Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet. 1980 Jul 5;2(8184):4–6. doi: 10.1016/s0140-6736(80)92888-3. [DOI] [PubMed] [Google Scholar]
  11. McNair A., Rasmussen S., Nielsen P. E., Rasmussen K. The antihypertensive effect of prazosin on mild to moderate hypertension, changes in plasma volume, extracellular volume and glomerular filtration rate. Acta Med Scand. 1980;207(5):413–416. doi: 10.1111/j.0954-6820.1980.tb09748.x. [DOI] [PubMed] [Google Scholar]
  12. Meland E. Kostholdsbehandling av essensiell hypertoni. Tidsskr Nor Laegeforen. 1983 Feb 10;103(4):271–274. [PubMed] [Google Scholar]
  13. Miller N. E., Thelle D. S., Forde O. H., Mjos O. D. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977 May 7;1(8019):965–968. doi: 10.1016/s0140-6736(77)92274-7. [DOI] [PubMed] [Google Scholar]
  14. Stanaszek W. F., Kellerman D., Brogden R. N., Romankiewicz J. A. Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs. 1983 Apr;25(4):339–384. doi: 10.2165/00003495-198325040-00002. [DOI] [PubMed] [Google Scholar]
  15. Vincent J., Elliott H. L., Meredith P. A., Reid J. L. Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol. 1983 Jun;15(6):719–725. doi: 10.1111/j.1365-2125.1983.tb01556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES